Metraipolis › archive › dc_4dcf830cb0bf

First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours — Europe PMC PMID:41471387

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41471387
DOI: 10.3390/ph18121898
License (as archived): solo-consultazione
Archived: 2026-11-07T14:02:59.816Z
SHA-256 of the archived text: af718a231aae6b0a7af3470691ef9a9084a87a69a75809a4c0168afa75419021
Stable URL of this page: https://metraipolis.com/documento/dc_4dcf830cb0bf

How to cite

First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours — Europe PMC PMID:41471387 — Europe PMC (en), https://europepmc.org/article/MED/41471387 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4dcf830cb0bf (Metraipolis archive dc_4dcf830cb0bf, sha256 af718a231aae6b0a7af3470691ef9a9084a87a69a75809a4c0168afa75419021)

BibTeX

@misc{dc4dcf830cb0bf,
  title = {First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours — Europe PMC PMID:41471387},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41471387},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4dcf830cb0bf; sha256 af718a231aae6b0a7af3470691ef9a9084a87a69a75809a4c0168afa75419021},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41471387. Agents can read the archived copy with the MCP tool read_document.